{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:58:46Z","timestamp":1789142326327,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40290-022-00433-z","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T16:03:24Z","timestamp":1656950604000},"page":"247-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research"],"prefix":"10.1007","volume":"36","author":[{"given":"Hu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Mawanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Goodloe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Motsko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"433_CR1","unstructured":"United States Food and Drug Administration. FDA drug safety communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use; 2015. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due. Accessed 3 June 2022."},{"issue":"1","key":"433_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085805","volume":"9","author":"WD Finkle","year":"2014","unstructured":"Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS\u00a0One. 2014;9(1): e85805.","journal-title":"PLoS\u00a0One"},{"issue":"17","key":"433_CR3","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2013.280386","volume":"310","author":"R Vigen","year":"2013","unstructured":"Vigen R, O\u2019Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829\u201336.","journal-title":"JAMA"},{"issue":"6","key":"433_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1530\/EJE-13-0321","volume":"169","author":"V Muraleedharan","year":"2013","unstructured":"Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725\u201333.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"433_CR5","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1210\/jc.2011-2591","volume":"97","author":"MM Shores","year":"2012","unstructured":"Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"433_CR6","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1177\/1060028014539918","volume":"48","author":"J Baillargeon","year":"2014","unstructured":"Baillargeon J, Urban RJ, Kuo YF, Ottenbacher KJ, Raji MA, Du F, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48(9):1138\u201344.","journal-title":"Ann Pharmacother"},{"key":"433_CR7","volume-title":"LEVITRA\u00ae (vardenafil hydrochloride) tablets, for oral use\u2014full prescribing information","author":"Bayer HealthCare Pharmaceuticals Inc.","year":"2017","unstructured":"Bayer HealthCare Pharmaceuticals Inc. LEVITRA\u00ae (vardenafil hydrochloride) tablets, for oral use\u2014full prescribing information. Whippany: Bayer HealthCare Pharmaceuticals Inc.; 2017."},{"key":"433_CR8","volume-title":"CIALIS\u00ae (tidalafil) tablets for oral use\u2014full prescribing information","author":"Lilly USA LLC","year":"2018","unstructured":"Lilly USA LLC. CIALIS\u00ae (tidalafil) tablets for oral use\u2014full prescribing information. Indianapolis: Eli Lilly and Company; 2018."},{"key":"433_CR9","volume-title":"VIAGRA\u00ae (sildenafil citrate) tablets, for oral use\u2014full prescribing information","author":"Pfizer Inc.","year":"2017","unstructured":"Pfizer Inc. VIAGRA\u00ae (sildenafil citrate) tablets, for oral use\u2014full prescribing information. New York: Pfizer Labs, Division of Pfizer Inc.; 2017."},{"key":"433_CR10","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1212\/WNL.0000000000009324","volume":"95","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Buse DC, Friedman BW, Feder L, Adams AM, Fanning KM, et al. Characterizing opioid use in a US population with migraine: results from the CaMEO study. Neurology. 2020;95:e457\u201368.","journal-title":"Neurology"},{"key":"433_CR11","unstructured":"United States Food and Drug Administration. FDA drug safety communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes; 2015. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory. Accessed 3 June 2022."},{"key":"433_CR12","volume-title":"ZOMIG\u00ae (zolmitriptan) nasal spray\u2014full prescribing information","author":"AstraZeneca","year":"2019","unstructured":"AstraZeneca. ZOMIG\u00ae (zolmitriptan) nasal spray\u2014full prescribing information. Bridgewater: Amneal Specialty, a division of Amneal Pharmaceuticals LLC; 2019."},{"key":"433_CR13","volume-title":"FROVA\u00ae (frovatriptan succinate) tablets, for oral use - full prescribing information","author":"Endo Pharmaceuticals Inc","year":"2013","unstructured":"Endo Pharmaceuticals Inc. FROVA\u00ae (frovatriptan succinate) tablets, for oral use - full prescribing information. Malvern: Endo Pharmaceuticals Inc.; 2013."},{"key":"433_CR14","volume-title":"AMERGE\u00ae (naratriptan hydrochloride) tablets, for oral use\u2014full prescribing information","author":"GlaxoSmithKline","year":"2016","unstructured":"GlaxoSmithKline. AMERGE\u00ae (naratriptan hydrochloride) tablets, for oral use\u2014full prescribing information. Research Triangle Park: GlaxoSmithKline; 2016."},{"key":"433_CR15","volume-title":"IMITREX\u00ae (sumatriptan succinate) injection, for subcutaneous use\u2014full prescribing information","author":"GlaxoSmithKline","year":"2019","unstructured":"GlaxoSmithKline. IMITREX\u00ae (sumatriptan succinate) injection, for subcutaneous use\u2014full prescribing information. Research Triangle Park: GlaxoSmithKline; 2019."},{"key":"433_CR16","volume-title":"AXERT\u00ae (almotriptan malate) tablets - full prescribing information","author":"Janssen-Ortho LLC","year":"2009","unstructured":"Janssen-Ortho LLC. AXERT\u00ae (almotriptan malate) tablets - full prescribing information. Raritan: Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009."},{"key":"433_CR17","volume-title":"MAXALT\u00ae (rizatriptan benzoate) tablets, for oral use\u2014full prescribing information","author":"Merck & Co. Inc.","year":"2011","unstructured":"Merck & Co. Inc. MAXALT\u00ae (rizatriptan benzoate) tablets, for oral use\u2014full prescribing information. Whitehouse Station: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; 2011."},{"key":"433_CR18","volume-title":"RELPAX\u00ae (eletriptan hydrobromide) tablets, for oral use\u2014full prescribing information","author":"Pfizer Inc.","year":"2013","unstructured":"Pfizer Inc. RELPAX\u00ae (eletriptan hydrobromide) tablets, for oral use\u2014full prescribing information. New York: Roerig, Division of Pfizer Inc.; 2013."},{"key":"433_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40122-020-00167-3","volume":"9","author":"H Li","year":"2020","unstructured":"Li H, Vincent M, Zhang X, Dennehy EB, Goodloe R, Aurora SK, et al. Acute migraine prescription patterns vary by baseline cardiovascular risk and clinical characteristics: a real-world evidence study. Pain Ther. 2020;9:499\u2013509.","journal-title":"Pain Ther"},{"issue":"19","key":"433_CR20","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D'Agostino Jr","year":"1998","unstructured":"D\u2019Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265\u201381.","journal-title":"Stat Med"},{"issue":"8","key":"433_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/pds.3386","volume":"22","author":"CD Mack","year":"2013","unstructured":"Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer AM, Sandler RS, et al. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf. 2013;22(8):810\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"433_CR22","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.jsxm.2017.09.010","volume":"14","author":"H Li","year":"2017","unstructured":"Li H, Mitchell L, Zhang X, Heiselman D, Motsko S. Testosterone therapy and risk of acute myocardial infarction in hypogonadal men: an administrative health care claims study. J Sex Med. 2017;14(11):1307\u201317.","journal-title":"J Sex Med"},{"issue":"10","key":"433_CR23","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1210\/jc.2011-1137","volume":"96","author":"AB Araujo","year":"2011","unstructured":"Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007\u201319.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"433_CR24","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1210\/jc.2016-1645","volume":"101","author":"GR Cunningham","year":"2016","unstructured":"Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Bhasin S, Matsumoto AM, et al. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab. 2016;101(8):3096\u2013104.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"433_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0025-6196(11)60963-4","volume":"82","author":"ER Bolona","year":"2007","unstructured":"Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):20\u20138.","journal-title":"Mayo Clin Proc"},{"issue":"7482","key":"433_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/bmj.38302.504063.8F","volume":"330","author":"M Etminan","year":"2005","unstructured":"Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ. 2005;330(7482):63.","journal-title":"BMJ"},{"key":"433_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2610","volume":"353","author":"T Kurth","year":"2016","unstructured":"Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353: i2610.","journal-title":"BMJ"},{"key":"433_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b3914","volume":"339","author":"M Schurks","year":"2009","unstructured":"Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339: b3914.","journal-title":"BMJ"},{"key":"433_CR29","unstructured":"Ali AK, Motsko SP, Swain JL, editors. Assessment of residual confounding and selection bias in studies of anti-diabetes medications. International conference on pharmacoepidemiology and therapeutic risk management, August 20\u201326, 2015. Boston: Pharmacoepidemiology and Drug Safety."},{"issue":"2","key":"433_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.mayocp.2014.10.011","volume":"90","author":"A Morgentaler","year":"2015","unstructured":"Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90(2):224\u201351.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"433_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jacc.2015.12.005","volume":"67","author":"RA Kloner","year":"2016","unstructured":"Kloner RA, Carson C 3rd, Dobs A, Kopecky S, Mohler ER 3rd. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016;67(5):545\u201357.","journal-title":"J Am Coll Cardiol"},{"issue":"4 Pt 1","key":"433_CR32","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1111\/j.1743-6109.2009.01690.x","volume":"7","author":"G Corona","year":"2010","unstructured":"Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med. 2010;7(4 Pt 1):1557\u201364.","journal-title":"J Sex Med"},{"key":"433_CR33","doi-asserted-by":"crossref","unstructured":"Kolodner K, Lipton RB, Lafata JE, Leotta C, Liberman JN, Chee E, Moon C. Pharmacy and medical claims data identified migraine sufferers with high specificity but modest sensitivity. J Clin Epidemiol. 2004;57(9):962\u201372.","DOI":"10.1016\/j.jclinepi.2004.01.014"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-022-00433-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-022-00433-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-022-00433-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T13:33:49Z","timestamp":1659015229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-022-00433-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1007\/s40290-022-00433-z","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"2 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sponsorship for this study\u00a0and its open access publication was provided by Eli Lilly and Company (Indianapolis, IN, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Francis Mawanda, Robert Goodloe, and Maurice Vincent are full-time employees of Eli Lilly and Company, Indianapolis, IN, USA and are minority holders of company stock. Lucy Mitchell is a full-time employee of Eli Lilly and Company, Lilly UK, Surrey, United Kingdom and a minority holder of company stock. At the time the study was conducted, Xiang Zhang, Stephen Motsko and Hu Li were full-time employees of Eli Lilly and Company, Indianapolis, IN, USA and minority holders of company stock. Xiang Zhang is currently affiliated with CSL Behring, King of Prussia, PA, USA. Hu Li is currently affiliated with Gilead Science, Foster City, USA. Stephen Motsko is currently affiliated with Amgen, Thousand Oaks, USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on a retrospective analysis of de-identified patient data from the United States healthcare system and does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Study analyzed anonymously using secondary data: Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Study analyzed anonymously using secondary data: Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6\u00a0months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"HL and SM were involved in study conception and design. LM XZ, and RG performed data analysis. HL, FM, XZ, MV, and SM provided data interpretation. HL, FM, LM, XZ, RG, MV, and SM were involved in drafting\/revising the article. HL, FM, LM, XZ, RG, MV, and SM provided final approval of the version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}